Under a tenth of people who could benefit from weight-loss injections such as Wegovy can access them, states the World Health Organization as it issues its initial guidance on the medications.
With in excess of 1,000,000,000 people worldwide currently living with obesity, it is advocating for more widespread and fairer access to GLP-1 medication.
Per forecasts, in excess of 2,000,000,000 will be obese by 2030 if no action is taken.
"The latest guidelines acknowledges that obesity is a chronic disease that can be treated with comprehensive and lifelong support," remarked its chief Tedros Adhanom Ghebreyesus.
Significant expense, limited production capacity, and logistical bottlenecks are significant hurdles to broad availability to the injections that can help people shift substantial weight, explains the body.
Skinny Jab Shortage
Even under the current best projected outlook, the supply of GLP-1 therapies would only suffice for around 100 million people – fewer than 10% of eligible patients, as stated by the health organization.
The recommendation urges governments and firms to widen availability, by approaches such as licensing agreements.
A patent on a key compound – the core ingredient of the drug Wegovy – is set to lapse in several countries in 2026.
How Weight-Loss Jabs Work
The injections mimick a natural hormone to reduce digestion speed, curb appetite and boost satiety so individuals eat less.
People typically begin shedding pounds in the initial weeks of starting on the regular doses.
Evidence indicates users may see weight return within a year of stopping the drug, because their usual food cravings return.
To be overweight or obese elevates your likelihood for developing diseases, like type 2 diabetes, cardiovascular issues, brain attack, and certain cancers.
Obesity impacts individuals in countries worldwide and was linked to over three and a half million fatalities worldwide in 2024, according to the WHO.
